After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Most recently, Yahoo Finance reported about the stock as it publicized that Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, REVB falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $3.65 and fluctuated between $4.0828 as its day high and $3.6000 as its day low. The current market capitalization of Revelation Biosciences Inc is $1.46M. A total of 0.49 million shares were traded on the day, compared to an average of 332.95K shares.
In the most recent transaction, TIDMARSH GEORGE F sold 27,771 shares of REVB for 0.52 per share on Dec 08. After the transaction, the Director now owns 0 company shares. In a previous transaction on Oct 16, TIDMARSH GEORGE F sold 10,957 shares at 0.66 per share. REVB shares that Director owns now total 42,096.
Among the insiders who sold shares, TIDMARSH GEORGE F disposed of 1,845 shares on Oct 16 at a per-share price of $0.65. This resulted in the Director holding 27,771 shares of REVB after the transaction. In another insider transaction, TIDMARSH GEORGE F sold 1,429 shares at $0.69 per share on Sep 28. Company shares held by the Director now total 42,096.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for REVB in the last 3 months, the mean price target is $343.50 with high estimates of $450.00 and low estimates of $237.00. In terms of 52-week highs and lows, REVB has a high of $67.80 and a low of $2.40.
As of this writing, REVB has an earnings estimate of -$13.8 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$13.8 per share and a lower estimate of -$13.8. The company reported an EPS of -$7.5 in the last quarter, which was 37.50% higher than expectations of -$12.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. REVB’s latest balance sheet shows that the firm has $1.27M in Cash & Short Term Investments as of fiscal 2021. There were $16.75k in debt and $2.14M in liabilities at the time. Its Book Value Per Share was $42.01, while its Total Shareholder’s Equity was -$99.47k.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for REVB is Buy with a score of 5.00.
